Methods for treatment comprising an antibody that binds CD223 protein
US10787513B2 · kind B2 · utility
1Cited by
15References
25Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 18, 2015 |
| Grant date | Sep 29, 2020 |
| Priority date | — |
| Expiry date | Feb 23, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anti-CD223 antibodies overcome immune suppression in cancer patients. The anti-CD223 antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.